GTCM
ACAD icon

Gyon Technologies Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Gyon Technologies Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-14,093
Closed -$199K – 349
2022
Q2 		$199K Buy
+14,093
New +$263K 0.06% 426

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Gyon Technologies Capital Management's ACAD Position: Q3 2022 in Review

Gyon Technologies Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q3 2022, closing a stake of 14,093 shares — an estimated $199K sold.

Gyon Technologies Capital Management first reported a position in ACAD in Q2 2022 and held it in 1 quarter. The position peaked at $199K in Q2 2022. 223 funds tracked by Wall St. Rank hold ACAD as of Q3 2022.

  • Gyon Technologies Capital Management reported no remaining Acadia Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Gyon Technologies Capital Management sold 14,093 Acadia Pharmaceuticals shares in Q3 2022, an estimated $199K.
  • Gyon Technologies Capital Management first reported a position in Acadia Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Gyon Technologies Capital Management's Acadia Pharmaceuticals position peaked at $199K in Q2 2022.
  • 223 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2022.

Based on Gyon Technologies Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.